We are live on ! Find out more
OCA

Octagon Capital Advisors Portfolio holdings

AUM $904M
1-Year Est. Return 737.04%
This Fund
S&P 500
This Quarter Est. Return
+34.55%
1 Year Est. Return
+737.04%
3 Year Est. Return
+2,554.78%
5 Year Est. Return
+4,333.84%
10 Year Est. Return
–
AUM
$904M
AUM Growth
+$79.9M
Cap. Flow
-$24.2M
Cap. Flow %
-2.67%
Top 10 Hldgs %
68.62%
Holding
34
New
7
Increased
7
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$31.9M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$22.6M
3
TERN
Terns Pharmaceuticals
TERN
+$21.8M
4
IRON icon
Disc Medicine
IRON
+$18.7M
5
AKTS
Aktis Oncology
AKTS
+$18.7M

Top Sells

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$27.2M
2
CDTX
Cidara Therapeutics
CDTX
+$22.1M
3
RAPT
RAPT Therapeutics
RAPT
+$19.4M
4
TRVI icon
Trevi Therapeutics
TRVI
+$14.9M
5
PHVS icon
Pharvaris
PHVS
+$13.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PHVS icon
26
Pharvaris
PHVS
$2.41B
$4.66M 0.52%
165,000
-506,465
-75% -$13.5M
CATX icon
27
Perspective Therapeutics
CATX
$332M
$3.3M 0.37%
+791,555
New +$3.34M
EVMN
28
Evommune Inc
EVMN
$412M
$3.3M 0.37%
143,472
-356,528
-71% -$8.06M
GOSS icon
29
Gossamer Bio
GOSS
$73.1M
$2.55M 0.28%
7,750,000
-6,165,371
-44% -$9.69M
CDTX
30
DELISTED
Cidara Therapeutics
CDTX
– –
-100,000
Closed -$22.1M
CGON icon
31
CALL
CG Oncology
CGON
$6.31B
– –
-600,000
Closed -$24.9M
CRBP icon
32
Corbus Pharmaceuticals
CRBP
$167M
– –
-955,000
Closed -$7.77M
PEPG icon
33
PepGen
PEPG
$154M
– –
-700,000
Closed -$4.56M
RAPT
34
DELISTED
RAPT Therapeutics
RAPT
– –
-574,000
Closed -$19.4M
1
2

Similar funds

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
AOWM
Asset One Wealth Management Bellevue, Washington $904M AUM
SWM
Sendero Wealth Management San Antonio, Texas $904M AUM 22.78% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $905M AUM
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
PSCM
Per Stirling Capital Management Austin, Texas $905M AUM 17.06% 1-Year Est. Return
EWM
Evermay Wealth Management Arlington, Virginia $902M AUM 14.76% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Octagon Capital Advisors's Q1 2026 Portfolio in Review

As of Q1 2026, Octagon Capital Advisors held 34 positions worth $904M, up 9.7% from $824M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Octagon Capital Advisors's Q1 2026 filing shows 7 new, 7 increased, 9 reduced and 5 closed positions. Its largest new stake was Mirum Pharmaceuticals: 338,900 shares worth $31.3M. The largest sale was Dianthus Therapeutics, an estimated $27.2M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 97% a quarter earlier.

  • Octagon Capital Advisors's largest Q1 2026 buy was Mirum Pharmaceuticals: 338,900 shares worth $31.3M.
  • Octagon Capital Advisors added most to Alumis Inc in Q1 2026, an estimated $7.5M increase.
  • Octagon Capital Advisors's biggest Q1 2026 reduction was Dianthus Therapeutics, cutting an estimated $27.2M.
  • Octagon Capital Advisors fully exited Cidara Therapeutics in Q1 2026, selling an estimated $22.1M.
  • Octagon Capital Advisors's ten largest holdings make up 69% of its $904M portfolio in Q1 2026.
  • Octagon Capital Advisors opened 7 new positions and closed 5 in Q1 2026.
  • Octagon Capital Advisors's portfolio value rose 9.7% quarter-over-quarter to $904M.

Based on Octagon Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.